Miguel Martín

Although breast cancer mortality has reduced by more than 40% in most high-income countries, a Lancet commission warns that one million people will die from the disease by 2040, especially in low- and middle-income countries. The authors highlight some of the knowledge gaps that persist about the disease, such as the lack of knowledge about the number of patients living with metastatic breast cancer and their needs, or the costs associated with breast cancer - including physical, psychological, social and economic costs - which, according to the authors, are immense but underestimated, and not adequately reflected in global health indicators. 

A study published in JAMA Network Open has followed 1,340 women with high-risk operable breast cancer. Analysing their lifestyles before, during and after treatment, the researchers conclude that those who followed a healthier pattern - including physical activity, no smoking, high fruit and vegetable intake, and low consumption of meat and sugary drinks - had a 37% lower risk of relapse and a 58% higher chance of survival than those who followed a worse pattern. Although the improvements in absolute risk were much smaller, the authors conclude that "lifestyle interventions may be a safe, inexpensive and feasible adjuvant strategy to delay and prevent recurrence and death from the world's most common cancer".

A study published today in the NEJM examines the risk of relapse in breast cancer patients who decide to pause endocrine therapy to try to become pregnant. The results show that temporarily stopping treatment does not confer an increased risk in the long term, but the authors warn of the need for further follow-up.

A phase 2 clinical trial has tested a type of immunotherapy based on oncolytic viruses in combination with chemotherapy for the treatment of triple-negative breast tumours. The results are published in the journal Nature Medicine.